The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Abstract
PURPOSE: Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy. We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy. PATIENTS AND METHODS: Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy. Estrogen receptor (ER) and progesterone receptor (PR) status was determined immunohistochemically from histologically representative formalin-fixed paraffin-embedded tumor samples. ER status was ascertained by mRNA in situ hybridization. RESULTS: Thirty-five (70%) of 50 primary tumors were positive for ER and 30 (60%) for PR. Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%). Discordant cases were due to the loss of ER (n = 6), loss of PR (n = 6), or loss of both receptors (n = 6). Receptor-negative primary tumors were always accompanied by receptor-negative recurrences. Among 27 patients with ER-positive primary tumors, loss of ER was a significant predictor (P = .0085) of poor response to subsequent endocrine therapy. Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression. CONCLUSION: Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients. We conclude that analysis of recurrent tumor samples may improve the predictive value of ER and PR assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.-M., Argos, P., & Chambon, P. (1986) · Nature · doi:10.1038/320134a0 · Cited by 2,321
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
The value of estrogen and progesterone receptors in the treatment of breast cancer
Osborne, C. K., Yochmowitz, M. G., Knight, W. A., & McGuire, W. L. (1980) · Cancer · doi:10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u · Cited by 720
Histological Typing of Breast Tumors
World Health Organization, G., Azzopardi, J. G., Chepick, O. F., Hartman, W. H., Jafarey, N. A., Llombard-Bosch, A., Ozzello, L., Rilke, F., Sasano, N., Sobin, L. H., et al. (1982) · Tumori Journal · doi:10.1177/030089168206800301 · Cited by 444
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Possible role of tissue‐bound calcium ions in citrate‐mediated high‐temperature antigen retrieval
Morgan, J. M., Navabi, H., Schmid, K. W., & Jasani, B. (1994) · The Journal of Pathology · doi:10.1002/path.1711740410 · Cited by 185
Multiple estrogen receptor assays in human breast cancer.
Hull, D. F., Clark, G. M., Osborne, C. K., Chamness, G. C., Knight, W. A., & McGuire, W. L. (1983) · PubMed · Cited by 174
Castles, C. G., Fuqua, S. A. W., Klotz, D. M., & Hill, S. M. (1993) · PubMed · Cited by 132
The variability of estrogen receptors in metastatic breast cancer
Brennan, M. J., Donegan, W. L., & Appleby, D. E. (1979) · The American Journal of Surgery · doi:10.1016/0002-9610(79)90159-4 · Cited by 88
Heterogeneity in hormone receptor status in primary and metastatic breast cancer.
Ck, O. (1985) · PubMed · Cited by 66
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Metadata
- Authors
- Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-09
- Volume
- 14
- Issue
- 9
- Pages
- 2584-2589
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1821522531
- Cited by
- 358
- References
- 15
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. https://app.cochat.ai/papers/10.1200/jco.1996.14.9.2584
- The paper
- Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996). Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.9.2584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
